Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PAVmed ( (PAVM) ) has shared an announcement.
On June 18, 2025, PAVmed Inc. held its annual meeting of stockholders, where approximately 77.2% of shares were represented. During the meeting, stockholders elected management’s nominees for director, approved the issuance of common stock upon exercise of pre-funded warrants, amended the 2014 Long-Term Incentive Equity Plan to increase available shares, approved executive compensation, and ratified the appointment of Marcum LLP as the independent registered certified public accounting firm for 2025.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score reflects a combination of financial challenges and strategic positives. While the company is on a path of strategic expansion and has shown some financial improvements, significant operational and cash flow issues remain. The technical indicators suggest bearish momentum, and while the valuation appears favorable, the lack of dividends and high leverage are concerns. The earnings call highlighted strategic initiatives that slightly outweigh the risks, contributing positively to the score.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
Average Trading Volume: 162,759
Technical Sentiment Signal: Sell
Current Market Cap: $10.81M
Learn more about PAVM stock on TipRanks’ Stock Analysis page.